Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients

Pruneta-Deloche, Valérie; Ponsin, Gabriel; Groisne, L.; Fruchart‐Najib, Jamila; Lagarde, Michel; Moulin, Philippe

doi:10.1016/j.atherosclerosis.2005.01.034

Cited by 30 publications

(23 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recently human APOA5 concentration was shown not to be related to VLDL kinetic parameters in 15 healthy control subjects [24]. Moreover, in a postprandial study in patients with type 2 diabetes a lack of correlation between plasma APOA5 levels and an index for lipoprotein lipase activity was found [22]. This was confirmed in the present study where no relationship between plasma APOA5 levels and plasma post-heparin lipoprotein lipase activity could be found (data not shown).…”

Section: Discussionsupporting

confidence: 75%

“…In contrast, all VLDL particles are carrying one or more APOC3 molecules. Average plasma APOA5 levels have been reported in healthy normolipidaemic volunteers of Caucasian origin as 16 μg/100 ml [19] and 1 μg/100 ml [22], and in healthy Japanese subjects as 18 μg/100 ml [17]. In our patients with type 2 diabetes, who were of Caucasian origin and had moderately elevated plasma triglyceride levels, plasma APOA5 levels were 7 to 139 μg/100 ml.…”

Section: Discussionmentioning

confidence: 48%

See 1 more Smart Citation

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

et al. 2006

View full text Add to dashboard Cite

Aims/hypothesis: Variation in the human apolipoprotein (APO) A5 gene (APOA5) is associated with elevated plasma triglycerides. However, data on the exact role of plasma concentrations of APOA5 in human triglyceride homeostasis are lacking. In the present study, we estimated plasma APOA5 levels in patients with type 2 diabetes at baseline and during atorvastatin treatment, a lipid-lowering treatment that results in a reduction in plasma triglycerides and APOC3. Subjects, materials and methods: Plasma APOA5 concentration was measured by ELISA in 215 subjects with type 2 diabetes, who were taken from the Diabetes Atorvastatin Lipid-lowering Intervention (DALI) study, a 30-week randomised, double-blind, placebo-controlled study, and given atorvastatin 10 mg or 80 mg daily. Results: At baseline, average plasma APOA5 concentration was 25.7±15.6 μg/100 ml. Plasma APOA5 (R s =0.40), APOC3 (R s =0.72) and APOE (R s =0.45) were positively correlated with plasma triglyceride levels (all p<0.001). In multiple linear regression analysis, adjusted for age and sex, the variation in plasma triglycerides was explained mostly by APOC3 (52%) and only to a small extent by APOA5 (6%) and APOE (1%). Atorvastatin treatment decreased plasma triglycerides, APOA5, APOC3 and APOE (all p<0.0001). After treatment, APOC3 remained the major determinant of plasma triglyceride levels (59%), while the contributions of APOA5 and APOE were insignificant (2 and 3%). Conclusions/interpretation: Our findings reveal a positive association between plasma APOA5 and triglycerides in patients with type 2 diabetes. Treatment with atorvastatin decreased plasma APOA5, APOC3, APOE and triglycerides. In contrast to APOC3, APOA5 is not a major determinant of triglyceride metabolism in these patients.

show abstract

Section: Discussionsupporting

confidence: 75%

Section: Discussionmentioning

confidence: 48%

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

et al. 2006

View full text Add to dashboard Cite

show abstract

“…On the other hand, in hypertriglyceridaemic subjects a significant positive correlation between plasma apoAV and triglyceride levels was observed (F. G. Schaap et al, unpublished results). Hypertriglyceridaemic patients with type 2 diabetes were reported to have fasting plasma apoAV levels similar to those of controls [37]. During postprandial hypertriglyceridaemia, plasma apoAV increased in these patients and remained unchanged in controls.…”

Section: Discussionmentioning

confidence: 95%

“…Recently, ELISA methods have been developed for determination of apoAV levels in human plasma ( [35][36][37] and F. G. Schaap et al, unpublished results); Western blotting [1] is the only technique currently available for measuring apoAV in rats. Cross-reactivity of antibodies employed in our own ELISA with rat apoAV was insufficient to allow quantification of apoAV in rat samples.…”

Section: Western Blottingmentioning

confidence: 99%

Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats

Dorfmeister

Brandlhofer

Schaap³

et al. 2006

Diabetologia

View full text Add to dashboard Cite

show abstract

“…On the other hand, in humans, the association of apoA-V and plasma TG levels is controversial. Some studies have demonstrated the association between several polymorphisms within the apoA-V locus and plasma TG levels 7,8) ; however, the association between apoA-V levels and TG levels is not always demonstrated in humans [9][10][11] , although apoA-V genetic variants reduced apoA-V levels…”

mentioning

confidence: 99%

Apolipoprotein A-V is a Potent Modulator of HDL and VLDL Components in Preadolescent Children

Abe

Okada

Kuromori

et al. 2009

JAT

View full text Add to dashboard Cite

Aim:Mice lacking apolipoprotein A-V (apoA-V) displayed an increase in serum triglyceride (TG) levels; however, the correlation of apoA-V levels with TG levels in humans is controversial, and the exact mechanism by which apoA-V affects TG levels is unclear. The aim of the present study was to clarify the impact of apoA-V on the lipoprotein subclass profile in preadolescent children, which has not been studied. Method: The study subjects were 178 (89 male, 89 female) 4th grade elementary school children (mean SD: 9.5 0.5 years old). ApoA-V levels were determined by an enzyme-linked immunosorbent assay, and the lipid component of each lipoprotein fraction and their particle sizes were measured by HPLC. Results: Levels of apoA-V showed no gender difference in preadolescent children, and were not affected by anthropometric variables. ApoA-V had a negative association with serum TG levels and TG levels in each lipoprotein fraction, and a positive association with HDL-C. In particular, apoA-V appears to contribute to the increase in cholesterol levels in the larger HDL fraction. Conclusions: It was suggested that apoA-V is a potent modulator of HDL and VLDL components in preadolescent children. J Atheroscler

show abstract

Postprandial increase of plasma apoAV concentrations in Type 2 diabetic patients

Cited by 30 publications

References 11 publications

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats

Apolipoprotein A-V is a Potent Modulator of HDL and VLDL Components in Preadolescent Children

Contact Info

Product

Resources

About